First author 英語論文

  1. Reconsidering the meaning of curing primary breast cancer as a systemic disease. Front Oncol, 2021 (in press).
  2. Clinical perspectives in addressing unsolved issues in (neo)adjuvant therapy for primary breast cancer. Cancers (Basel) 13: 926, 2021.
  3. Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer. Transl Oncol 14:100927, 2021.
  4. Outpatient breast-conserving surgery for breast cancer: Use of local and intravenous anesthesia and/or sedation may reduce recurrence and improve survival. Ann Med Surg (Lond) 60:365-371, 2020.
  5. The persisting complexity of relationships between anesthetic techniques and cancer recurrence in oncological surgery. Int J Surg 81: 98-99, 2020.
  6. Anesthetic techniques and recurrence of breast cancer: Unanswered questions. Gland Surg 9: 490-4, 2020.
  7. Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 46:77-84, 2020.
  8. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients. Cancer Immunol Immunother 68:577-85, 2019.
  9. Outcomes of outpatient breast cancer surgery at a private breast clinic. Breast J 24:628-32, 2018.
  10. Anesthetic technique for cancer surgery: Harm or benefit for cancer recurrence? Eur J Surg Oncol 44:557-8, 2018.
  11. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med 16:8, 2018.
  12. Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin Transl Med 6:34, 2017.
  13. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev 36:159-77, 2017.
  14. Cancer immunoediting from immune surveillance to immune escape 121:1-14, 2007.
  15. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121:149-57, 2007.
  16. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7:1006-16, 2006.
  17. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5:1429-42, 2006.
  18. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Therapy 14:1-11, 2007.
  19. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146:189-96, 2006.
  20. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumor immunity. Immunology 119:254-64, 2006.
  21. Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17:1213-20, 2006.
  22. Potential role of HER-2 in primary breast tumor with bone metastasis. Oncol Rep 15:1477-84, 2006.
  23. Tumor-driven evolution of immunosuppressive network during malignant progression. Cancer Res 66:5527-36, 2006.
  24. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 32:269-77, 2006.
  25. Regulation and interplay of apoptotic and nonapoptotic cell death. J Pathol 208:319-26, 2006.
  26. Role of the unfolded protein response in cell death. Apoptosis 11:5-13, 2006.
  27. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4:924-33, 2005.
  28. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 21:1-9, 2005.
  29. Caspase-dependent and -independent cell death pathways after DNA damage. Oncol Rep 14:595-9, 2005.
  30. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-43, 2005.
  31. Assay directed chemotherapy: clinical benefit remains unclear. Cancer Treat Rev 31:151-4, 2005.
  32. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103:2199-207, 2005.
  33. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Int J Oncol 26:1025-31, 2005.
  34. Chemosensitization by STI571 targeting the PDGF/PDGFR-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103:1800-9, 2005.
  35. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103:1551-60, 2005.
  36. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer 6: 223-32, 2005.
  37. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101:2491-502, 2004.
  38. Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells. Int J Mol Med 14:697-706, 2004.
  39. Preclinical evaluation of antisense Bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 101:2177-86, 2004.
  40. The role of FasL and TGF-β in tumor progression; Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100:2281-91, 2004.
  41. Multidisciplinary approach to cancer treatment: A model for breast cancer treatment at the M.D. Anderson Cancer Center. Int J Clin Oncol 9:356-63, 2004.
  42. Neoadjuvant chemotherapy for local advanced breast cancer with Stage IIIB. Oncol Rep 11:1265-72, 2004.
  43. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer. Int J Oncol 24:5-17, 2004.
  44. Changes in therapy for solid tumors: Potential for overcoming drug resistance in vivo with molecular targeting agents. Surgery Today 34:293-303, 2004.
  45. Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations. Anti-Cancer Drugs 14:715-23, 2003.
  46. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells. Oncol Rep 10:1925-30, 2003.
  47. Clinical relevance of meta-analysis of survival benefit when deciding treatment of adjuvant chemotherapy in gastric cancer. Anticancer Res 23:1843-6, 2003.
  48. Factors that influence the incidence of microscopic carcinoma in frozen and preserved specimens from patients with breast carcinoma after breast-conserving surgery. Oncol Rep 10:1321-28, 2003.
  49. Effects of introduction of dThdPase cDNA on sensitivity to 5’-deoxy-5-fluorouridine and tumor angiogenesis. Int J Oncol 22:835-41, 2003.
  50. Effect of Bcl-2 antisense oligonucleotides on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med 11:799-804, 2003.
  51. Feasibility and therapeutic efficacy of weekly 1-hour low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep 10:145-50, 2003.
  52. Inducing cancer cell death by targeting transcription factors. Anti-Cancer Drugs 14:3-11, 2003.
  53. Current status of the molecular mechanisms of anticancer drug-induced apoptosis -The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343-52, 2002.
  54. Adjuvant therapy for colorectal cancer. Anticancer Res 22:2413-8, 2002.
  55. Utility of techinetium-99m methoxyisobutylisonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer. Breast Cancer 9:240-7, 2002.
  56. Mechanism(s) of antitumor action in protracted infusion of low-dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20:549-55, 2002.
  57. Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res 22:283-90, 2002.
  58. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol Rep 9:3-9, 2002.
  59. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol 18:363-7, 2001.
  60. A phase II trial of mitomycin C, 5’-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action. Oncol Rep 8:597-603, 2001.
  61. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery. Breast Cancer 8:146-52, 2001.
  62. Effect of inhibitors of cysteine and serine proteases in anticancer drug-induced apoptosis in gastric cancer cells. Int J Oncol 18:1227-32, 2001.
  63. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. Oncol Rep 8:1171-6, 2001.
  64. A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein. Int J Oncol 19:1075-80, 2001.
  65. Significance of lymphoscintigraphic mapping with Tc-99m human serum albumin and tin colloid in sentinel lymph node biopsy in breast cancer. Int J Oncol 19:991-6, 2001.
  66. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 in bax-transfected gastric cancer cells. Anticancer Res 20:439-44, 2000.
  67. An analysis of the therapeutic efficacy of protracted infusion of low dose of 5-fluorouracil and cisplatin to advanced gastric cancer. J Infect Chemother 6:222-8, 2000.
  68. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells. Int J Oncol 15:751-6, 1999.
  69. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 15:921-6, 1999.
  70. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer drugs in association with apoptosis. Anticancer Res 19:1779-86, 1999.
  71. Expression and relationship between topoisomerase I and II alpha genes in tumors and normal tissues in esophageal, gastric and colon cancers. Anticancer Res 19:5393-8, 1999.
  72. Taxotere activates transcription factor AP-1 in association with cell death in gastric cancer cell lines. Anticancer Res 19:5399-406, 1999.
  73. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA binding activity, and formation of Jun/Fos family dimmers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 54:4958-66, 1994.
  74. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-6, 1992.
  75. Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissues. Jpn J Surg (Surgery Today) 21:590-3, 1991.
  76. mRNA expression of topoisomerase II in human tumors and normal tissues. Jpn J Surg (Surgery Today) 21:587-9, 1991.
  77. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11:429-32, 1991.
  78. Factors contributing to adriamycin sensitivity in human xenografts tumors: the relationship between expression of the MDR1, GST-pi and topoisomerase II genes and tumor sensitivity to adriamycin. Anticancer Res 12:241-6, 1991.
  79. Expression of the multidrug resistance gene in human tumors. Hiroshima J Med Sci 3:71-7, 1990.
  80. Prediction of the resistance of human tumors to adriamycin by chemosensitivity tests and DNA analysis of the multidrug resistance gene. Jpn J Surg (Surgery Today) 20:192-6, 1990.